

14. Biological Effects of MFIII PLACENTA HP®

Experiments have shown the effectiveness of Placenta HP for many different conditions.

Heals Skin Conditions, Burns and Wounds

Research has shown the positive effect of placenta extract on skin conditions. Bigliardi used a semi-greasy placenta ointment for acute radiodermatitis. With external application of this ointment, he discovered a drastic improvement in subjects' skin condition [1].

In many countries, intra-muscular and topical use of placental extract for burn injuries, chronic wounds and as post-surgical dressing is an age-old practice. Shimazaki et al. explored the use of amniotic membrane for patients with chemical and thermal burns. They studied and treated the eyes of patients with severe chemical burns with a transplant of amniotic membrane on the sclera. The amniotic membrane was not rejected in any of the case-studies. Scientists found that visual acuity markedly improved in each eye, and regenerated conjunctiva was stable with mild scarring [2].

Ramakrishnan et al. used amniotic membrane from HbSAg, HIV seronegative mothers as a temporary biological dressing on superficial and deep partial-thickness burns. They noted a reduction in pain, early drying of the wound and epithelialisation [3].

Furthermore, clinical trials with placental extract conducted by Shukla et al. have established healing of chronic, non-healing wounds [4]. Maral et al., Datta et al., Pafi et al., Muratore et al., Hanada et al., Sato et al. and Subramanyam found similar results in improving healing wounds and other skin conditions [5-13]. Placental extract has also been responsible for healing ulcerative lesions of lower limbs [14].

Reduces Pain

Oral sub-mucous fibrosis manifests as stiffness of oral mucosa, a burning sensation and an inability to eat. Katharia et al. utilised placenta extract to achieve results. Placenta extract was administered parenterally and effects were monitored in reducing the severity of the disease. There was significant improvement in mouth opening, colour of oral mucosa, burning sensation, and reduction of fibrous bands [15].

Treatment of Gastric or Duodenal Ulcers

The parenteral administration of Placenta HP for the treatment of gastric and duodenal ulcers was investigated in Japan, conducted by Nakazawa et al. Using endoscopic and X-ray technology as diagnostic tools, they found 95% of patients in the group treated with placenta extract were responsive to treatment [16]. Bianchini et al. found similar results [17].

Eases Inflammation

Sur et al. showed the anti-inflammatory effects of human placental extract by inducing inflammation in the hind paws of rats. They found a significant inhibition of paw oedema in the group treated with human placental extract [18].

Defies Malignancy

Using fast growing and undifferentiated rat tumour cells, Carbo et al. demonstrated the inhibitory action of rat pregnant plasma. Tumour cells from untreated rats were seeded in culture dishes with or without the presence of pregnant rat plasma. In comparison with cells that were grown in the presence of virgin rat plasma, there was a 34% decrease in growth in the culture dishes with pregnant rat plasma. Pregnant rat plasma induced apoptosis in tumour cells [19].

Inhibits Bacterial and Fungal Growth

Chakraborty et al. studied the role of Placenta HP on the growth of different bacteria. They found that Placenta HP prevents the growth of clinically isolated bacteria, such as *E. coli* from urine and blood culture. The found Placenta HP to also have an inhibitory role in the growth of bacteria such as *E. coli*, *Staphylococcus aureus*, and fungi such as *Saccharomyces cerevisiae*, *Kluyvero-mycetes fragilis*, and *Candida albicans* [20].

Inhibits Viral Growth

The factors controlling HIV-1 transmission from mother to infant are not clearly understood. Studies in the past have suggested the existence of maternal and placental protective mechanisms that inhibit viral replication in utero. Sharma et al. explored the role of placenta HP on the HIV-1 virus. Their studies demonstrated that a derivative of human placental stromal cells protected HIV-1 infected cells from virus-induced apoptosis and suppressed virus production [21].

Improvement of Mental and Intellectual Development

Grebennikova et al. analyzed the effect of transplantation of human foetal tissue on children with Down syndrome. They children underwent neuro-psychological testing before treatment, six months after the first transplantation, and six months after the second transplantation. They found a significant increase in mental development after six months of the first transplant, and a further increase after the second transplantation. They also noted an improvement in perception and control [22].

Placenta extract has also shown to aid in the treatment of Gaucher's disease, strengthen the kidneys and even prevent post natal depression. It has the potential to aid in the treatment and rejuvenation of a number of different conditions as it contains amino acids, vitamins and hundreds of enzymes.

Summary

Clinical application of placenta depends on age related symptoms. Fatigue, infertility, frozen shoulder, shoulder stiffness, migraine, joint pain, depression, skin ageing, acne, hay fever, pre-menstrual syndrome, uterine fibrosis, endometriosis, insomnia, liver dysfunction, fungal infection, digestive problems, nerve related discomfort, extreme coldness, anaemia, low libido, constipation, gastritis, or intestinal intoxication are considered as indications of placenta treatment. Such treatment attempts to regulate hormones including DHEA, estradiol, progesterone, testosterone, thyroid hormone, growth hormone, melatonin, and cortisol, which are all affected by the aging process. Placenta HP, with minimal side effects, can enhance and work synergistically with other modes of anti-aging management

15. Safety and Effectiveness of MFIII PLACENTA HP®

A number of studies have been conducted to ensure the safety of MFIII PLACENTA HP®. Decades of clinical experience also demonstrate the safety and effectiveness of Placenta Therapy. Placenta HP is a safe therapeutic agent with the potential to regenerate activity within all human tissue. When introduced into humans internally, it can reinforce deteriorating cells.

References

- [1] Bigliardi, P.; *Int. J. Tiss. React.*, 4, 153-154 (1982).
- [2] Shimazaki, J., Yang, H.Y. & Tsubota, K.; *Ophthalmology*, 104(12), 2068-2076 (1997).
- [3] Ramakrishnan, K.M., Jayaraman, V.; *Burns*, 23, S33-S36 (1997).
- [4] Shukla, V. K., Rasheed, M. A., Kumar, M., Gupta, S. K. & Pandey, S. S.; *Journal of Wound Care*, 13, 177-179 (2004).
- [5] Maral, T., Borman, H., Arslan, B., Demihani, B., Akinbingol, G., & Haberal, M.; *Burns*, 25, 625-635 (1999).
- [6] Datta, P. & Bhattacharyya, D.; *J. Pharm. Biomed. Anal.*, 34, 1091-1098 (2004).
- [7] Datta, P. & Bhattacharyya, D.; *J. Chromatogr. B.*, 818, 67-73 (2005).
- [8] Datta, P. & Bhattacharyya, D.; *J. Pharm. Biomed. Anal.*, 36, 211-218 (2004).
- [9] Pafi, S., Saumandal, B. K., Bhattacharyya, A. K. & Saumandal, P.; *J. Obstet. Gynaecol. India*, 51, 124-126 (2001).
- [10] Muratore, O., Pesce Schito A., Cattarini, G., Tonoli, E.L., Gianoglio, S., Schiappacasse, S., Felli, L., Picchetta, F., Schito, G.C.; *Cell Mol. Life Sci.*, 53(3), 279-285 (1997).
- [11] Hanada K, Shimazaki J, Shimmura S & Tsubota, K.; *Ann J Ophthalmol.*, 131(3), 324-331 (2001).
- [12] Sato H., Shimazaki J., & Shinazaki N.; *Invest Ophthalmol. Vis. Sci.*, 39, S428. (1998).
- [13] Subramanyam, M.; *British Journal of Plastic Surgery*, 48, 477-478 (1995).
- [14] Wajgi, G., Nardoianji, V., Antonelli, P., Cardini, P. & Rovere, V.; *Minerva Anestesiol.*, 16, 2-5 (1991).
- [15] Katharia, S.K., Singh, S.P. & Kulshreshtha, V.K.; *Indian Journal of Pharmacology*, 24(3), 181-183 (1992).
- [16] Nakazawa, S., Odori, Y., Mizuno, F., Naito, Y., Tsuboi, Y., Yamada, K., Hidano, H., Nagai, S., Takeyama, H., Ochiai, E., Numata, M., Ito, J., Tarumi, A., Takayama, T., Kitamura, K. & Watarai, K.; *Rinsho Hyoka*, 3, 139-148 (1973).
- [17] Bianchini, P., Tellini, N., Moroni, A. M. & Follani, M. G.; *Int. J. Tiss. React.*, 3, 151-154 (1981).
- [18] Sur, T.K., Biswas, T.K., Ali, L. & Mukherjee, B.; *Acta. Pharmacol. Sin.*, 2, 187-192 (2003).
- [19] Carbo, N., Lopez-Soriano, F.J., & Argiles, J.M.; *Oncology Reports*, 12, 885-887 (2004).
- [20] Chakraborty, P.D. & Bhattacharyya, D.; *Current Science*, 88(5), 782-786 (2005).
- [21] Sharma, U.K., Trujillo, J., Song, H., Saito, F.P., Laeyendecker, O.B., Castillo, R., Arango-Jaramillo, S., Sridharan, G., Dettenthaler, M., Blakemore, K., Yu, X. & Schwartz, D.H.; *Journal of Immunology*, 161, 6406-6412 (1998).
- [22] Grebennikova, N.V., Burkova, M.I., Molnar, E.M., Sukhildt, G.T., Fisenko, A.P. & Ionova, N.A.; *Klinicheskij Vestnik* (1995).